Drugs /
palbociclib
Overview
Biomarker-Directed Therapies
Clinical Trials
Palbociclib has been investigated in 149 clinical trials, of which 131 are open and 18 are closed. Of the trials investigating palbociclib, 3 are early phase 1 (3 open), 37 are phase 1 (34 open), 20 are phase 1/phase 2 (19 open), 66 are phase 2 (56 open), 2 are phase 2/phase 3 (1 open), 16 are phase 3 (14 open), 2 are phase 4 (1 open), and 3 are no phase specified (3 open).
ER Positive, HER2 Negative, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for palbociclib clinical trials.
Breast carcinoma, malignant solid tumor, and breast adenocarcinoma are the most common diseases being investigated in palbociclib clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.